| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8217083 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
| US8436051 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
Canasa is owned by Abbvie.
Canasa contains Mesalamine.
Canasa has a total of 2 drug patents out of which 0 drug patents have expired.
Canasa was authorised for market use on 05 November, 2004.
Canasa is available in suppository;rectal dosage forms.
The generics of Canasa are possible to be released after 06 June, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Sep 02, 2019 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
How can I launch a generic of CANASA before it's drug patent expiration?
More Information on Dosage
CANASA family patents
